Healthcare company Northwestern Medicine on Thursday published in the Journal of the American Medical Association (JAMA) the positive outcomes in the first 30 consecutive COVID-19 patients who underwent a lung transplant in Chicago.
The outcomes for the company's COVID-19 lung transplant patients are validated by a concurrent paper in New England Journal of Medicine (NEJM). Dr Ankit Bharat, the company's chief of thoracic surgery, reportedly performed the COVID-19 lung transplant.
Among the 102 consecutive lung transplant recipients from 21 January 2020 to 30 September 2021, about 30 patients were transplanted due to COVID-19 and 72 patients were transplanted due to chronic end-stage lung disease including cystic fibrosis, pulmonary hypertension, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, according to the company.
In June 2020, the company's surgeons performed the first lung transplant on a COVID-19 patient in the US. To date, 40 COVID-19 patients have received its lung transplants. For COVID-19 patients with irrecoverable lung damage, transplantation is the only option for survival.
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership
Vicinitas Therapeutics Launches with USD 65m in Series A Financing